Drug Development

Protocols: BU’s Outterson helms $350M antibiotics project; Adaptimmune lands on EMA’s inside track

Kevin Outterson of Boston University’s School of Law has been tapped to run the new CARB-X program, a $350 million, public/private project that will bring together partners on both sides of the Atlantic to spur the preclinical development of new antibiotics. HHS is providing $30 million to help fund the effort in its first year. Growing resistance to antibiotics has steadily raised the threat posed by new superbugs now in circulation.

The UK’s Adaptimmune has jumped on to the EMA’s new inside track. Its SPEAR T-cell therapy should now have an open door with regulators in Europe. “Access to the PRIME initiative represents an important regulatory opportunity for us,” noted CMO Rafael Amado. “It can provide early engagement on the development program with potential for accelerated assessment of data to companies like Adaptimmune who are developing new treatment modalities for patients in Europe with few or no treatment options.”

The antibiotics company Motif Bio has outlined plans for its IPO, looking to raise $35 million by offering 2.8 million shares at a price of $12.42. Renaissance Capital reports that insiders intend to purchase $9 million worth of the stock on offer.

Pfizer and Western Oncolytics are collaborating on preclinical and clinical development of an oncolytic virus program dubbed WO-12 through Phase I trials. Pfizer gets an exclusive option to acquire WO-12 in the deal, though no terms were disclosed.

Get Endpoints News in your inbox

Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.


Subscribe to Endpoints

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy